The Study on COgnition and Prognosis in the Elderly (SCOPE); outcomes in patients not receiving add-on therapy after randomization

Objective To assess clinical outcomes in the Study on COgnition and Prognosis in the Elderly (SCOPE) in patients who did not receive add-on antihypertensive therapy after randomization, i.e. in patients that best reflect the original intention of a placebo-controlled trial. Design Post-hoc analysis of a prospective, randomized, controlled trial. Settings and participants Five hundred and twenty-seven centres in 15 countries participated in SCOPE. Patients aged 70–89 years, with systolic blood pressure 160–179 mmHg and/or diastolic blood pressure 90–99 mmHg, and preserved cognitive function were eligible. Out of 4937 patients in SCOPE, 2098 did not receive add-on therapy. Intervention The number of patients who received candesartan 8–16 mg once daily was 1253, and 845 received placebo. Mean follow-up was 3.7 and 3.5 years, respectively. Main outcome measures Primary: major cardiovascular events (cardiovascular mortality, non-fatal stroke or non-fatal myocardial infarction). Secondary: total mortality, cardiovascular mortality, fatal and non-fatal myocardial infarction, fatal and non-fatal stroke, cognitive function, and dementia. Results The treatment groups were generally well balanced for baseline characteristics. Blood pressure fell by 21.8/11.0 mmHg in the candesartan group and by 17.2/8.4 mmHg in the placebo group. There were significant relative risk reductions with candesartan in major cardiovascular events (32%, P = 0.013), cardiovascular mortality (29%, P = 0.049), and total mortality (27%, P = 0.018). There were no significant differences between the treatment groups in cognitive outcomes. Both treatments were generally well tolerated. Conclusions Treatment of elderly patients with mild hypertension is beneficial and supports current recommendations. Candesartan appears an appropriate therapy in such patients, in view of its favourable tolerability profile and ability to reduce major cardiovascular events.

[1]  A. Hofman,et al.  The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial , 2003, Journal of hypertension.

[2]  A. Zanchetti,et al.  Antihypertensive treatment in patients with type-2 diabetes mellitus: what guidance from recent controlled randomized trials? , 2002, Journal of hypertension.

[3]  A. Hofman,et al.  Study on COgnition and Prognosis in the Elderly (SCOPE): Baseline Characteristics , 2000, Blood pressure.

[4]  M Ishii,et al.  [The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, and 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension]. , 2000, Nihon rinsho. Japanese journal of clinical medicine.

[5]  A. Hofman,et al.  Study on COgnition and Prognosis in the Elderly (SCOPE). , 1999, Blood pressure.

[6]  Jan A Staessen,et al.  Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension , 1997, The Lancet.

[7]  G. Mcinnes,et al.  The efficacy and tolerability of candesartan cilexetil in an elderly hypertensive population. , 1997, Journal of human hypertension.

[8]  C. Dollery,et al.  Medical Research Council trial of treatment of hypertension in older adults: principal results. , 1992 .

[9]  B. Dahlöf,et al.  Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension) , 1991, The Lancet.

[10]  Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. , 1991, JAMA.

[11]  Richard K. Reznick,et al.  Survival analysis: A practical approach , 1989, Diseases of the colon and rectum.

[12]  C. Berne,et al.  A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. , 1989, The New England journal of medicine.

[13]  C. Berne,et al.  Sensitivity to insulin during treatment with atenolol and metoprolol: a randomised, double blind study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients. , 1989, BMJ.

[14]  K Hirschhorn,et al.  Letter: Immunotherapy for colorectal cancer. , 1976, Lancet.